Updated on 19 August 2026
Expertise in Cancer Biology, Molecular Targets and Innovative Therapeutic Approaches
Lab Head at Institute of Biochemistry named after H Buniatian
Yerevan, Armenia
About
What we offer:
The H. Buniatian Institute of Biochemistry, NAS RA, offers expertise in molecular biochemistry, pharmacology, cancer-related molecular mechanisms, and translational biomedical research. Our research includes investigation of PRPS-1 as a potential molecular target in glioma and development of innovative approaches for cancer diagnosis and therapy.
We also have expertise in bioactive compounds, protein- and peptide-based approaches, oxidative stress, molecular mechanisms of cell proliferation, and experimental evaluation of therapeutic strategies.
What we are looking for:
We are seeking European research institutions, universities, hospitals, biotechnology and pharmaceutical companies interested in collaborative cancer research, particularly in molecular targets, glioma/glioblastoma, biomarker discovery, innovative therapeutics, and translational research.
Potential role:
Research partner contributing biochemical, pharmacological and preclinical expertise to Horizon Europe consortia and collaborative projects.
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
Translational Cancer Research & Precision Therapeutics
- Partner seeks Consortium/Coordinator
Kristine Danielyan
Lab Head at Institute of Biochemistry named after H Buniatian
Yerevan, Armenia
Project cooperation
Antibody/scFv Discovery & Functional Validation of Novel Cancer Targets
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
Oya Ari Uyar
Chief Senior Researcher at TUBITAK Marmara Research Center
Kocaeli, Türkiye
Project cooperation
From Genomic Hits to Therapeutic Targets: IMol as partner in Cancer Mission
- Partner seeks Consortium/Coordinator
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
Magdalena Grodecka
Commercialization coordinator at IMol PAS at IMol Polish Academy od Sciences
Warsaw, Poland